Publication Author: Sullivan_Sean
-
The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma.
Suh K, Carlson JJ, Xia F, Williamson T, Sullivan SD. The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma. J Manag Care Spe
rakerr2
-
Comparison of Alternative Methods to Assess the Cost-Effectiveness of Tumor-Agnostic Therapies: A Triangulation Approach Using Larotrectinib as a Case Study.
Briggs A, Wehler B, Gaultney JG, Upton A, Italiano A, Bokemeyer C, Paracha N, Sullivan SD. Comparison of Alternative Methods to Assess the Cost-Effectiveness of Tumor-Agnostic Therapies: A Triangulation Approach Using Larotrectinib as a Case Study. Value
rakerr2
-
International reference pricing of pharmaceuticals in the United States: Implications for potentially curative treatments.
Sullivan SD, Sullivan KD, Dabbous O, Garrison LP. International reference pricing of pharmaceuticals in the United States: Implications for potentially curative treatments. J Manag Care Spec Pharm. 2022 May;28(5):566-572. doi: 10.18553/jmcp.2022.28.5.566.
rakerr2
-
Successes and challenges of implementing a cancer care delivery intervention in community oncology practices: lessons learned from SWOG S1415CD.
Watabayashi KK, Bell-Brown A, Kreizenbeck K, Egan K, Lyman GH, Hershman DL, Arnold KB, Bansal A, Barlow WE, Sullivan SD, Ramsey SD. Successes and challenges of implementing a cancer care delivery intervention in community oncology practices: lessons learn
rakerr2
-
Cost-Effectiveness of the COVID-19 Test, Trace and Isolate Program in Colombia.
Guzmán Ruiz Y, Vecino-Ortiz AI, Guzman-Tordecilla N, Peñaloza-Quintero RE, Fernández-Niño JA, Rojas-Botero M, Ruiz Gomez F, Sullivan SD, Trujillo AJ. Cost-Effectiveness of the COVID-19 Test, Trace and Isolate Program in Colombia. Lancet Reg Health Am. 202
rakerr2
-
Diagnosis and management of TRK fusion cancer.
Kummar S, Italiano A, Brose MS, Carlson JJ, Sullivan SD, Lassen U, Federman N. Diagnosis and management of TRK fusion cancer. Am J Manag Care. 2022 Jan;28(2 Suppl):S15-S25. doi: 10.37765/ajmc.2022.88834. Review.
rakerr2
-
Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer.
Carlson JJ, Italiano A, Brose MS, Federman N, Lassen U, Kummar S, Sullivan SD. Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer. Am J Manag Care. 2022 Jan;28(2 Suppl):S26-S32. doi: 10.37765/ajmc.2022.88845. Review.
rakerr2
-
Variation in market access decisions for cell and gene therapies across the United States, Canada, and Europe.
Tunis S, Hanna E, Neumann PJ, Toumi M, Dabbous O, Drummond M, Fricke FU, Sullivan SD, Malone DC, Persson U, Chambers JD. Variation in market access decisions for cell and gene therapies across the United States, Canada, and Europe. Health Policy. 2021 Dec
rakerr2
-
FINE-CKD model to evaluate economic value of finerenone in patients with chronic kidney disease and type 2 diabetes.
Pochopień MT, Cherney DZI, Folkerts K, Levy P, Millier A, Morris S, Roy-Chaudhury P, Sullivan SD, Mernagh P. FINE-CKD model to evaluate economic value of finerenone in patients with chronic kidney disease and type 2 diabetes. Am J Manag Care. 2021 Dec;27(
rakerr2
-
Estimating Long-Term Survival Outcomes for Tumor-Agnostic Therapies: Larotrectinib Case Study.
Briggs A, Paracha N, Rosettie K, Upton A, Bokemeyer C, Lassen U, Sullivan SD. Estimating Long-Term Survival Outcomes for Tumor-Agnostic Therapies: Larotrectinib Case Study. Oncology. 2022;100(2):124-130. doi: 10.1159/000519767. Epub 2021 Nov 29.
rakerr2